CA2321259A1 - Dosage de telomerase preleve dans des liquides organiques utilise pour le depistage du cancer, l'evaluation du stade d'evolution de la maladie et l'etablissement du pronostic - Google Patents

Dosage de telomerase preleve dans des liquides organiques utilise pour le depistage du cancer, l'evaluation du stade d'evolution de la maladie et l'etablissement du pronostic Download PDF

Info

Publication number
CA2321259A1
CA2321259A1 CA002321259A CA2321259A CA2321259A1 CA 2321259 A1 CA2321259 A1 CA 2321259A1 CA 002321259 A CA002321259 A CA 002321259A CA 2321259 A CA2321259 A CA 2321259A CA 2321259 A1 CA2321259 A1 CA 2321259A1
Authority
CA
Canada
Prior art keywords
telomerase
cancer
telomerase activity
blood
body fluid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002321259A
Other languages
English (en)
Inventor
Jeffrey W. Strovel
Judith Stamberg
Edward Highsmith
Lynne V. Abruzzo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Maryland at Baltimore
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2321259A1 publication Critical patent/CA2321259A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Les taux élevés de l'activité de la télomérase dans des extraits de tissus et de cellules ont été utilisés pour le dépistage du cancer dans un échantillon tissulaire. Cette invention concerne un dosage amélioré d'un protocole d'amplification télomérique répétée (TRAP) pour quantifier l'ARN télomérase ou les taux d'activité de la télomérase, en utilisant des liquides organiques pouvant être obtenus facilement, tels que le sang, le plasma, la lymphe, le liquide pleural, le liquide céphalorachidien spinal, la salive, l'expectoration, l'urine et le sperme pour à la fois dépister le cancer, et évaluer le stade d'évolution de la maladie chez un patient et en établir le pronostic. Par ailleurs, on peut utiliser le dosage TRAP amélioré comme marqueur diagnostique tumoral et comme moyen de surveillance de l'évolution et de l'efficacité des cancérothérapies.
CA002321259A 1998-02-16 1999-02-16 Dosage de telomerase preleve dans des liquides organiques utilise pour le depistage du cancer, l'evaluation du stade d'evolution de la maladie et l'etablissement du pronostic Abandoned CA2321259A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US7479398P 1998-02-16 1998-02-16
US60/074,793 1998-02-16
PCT/US1999/003302 WO1999041406A1 (fr) 1998-02-16 1999-02-16 Dosage de telomerase preleve dans des liquides organiques utilise pour le depistage du cancer, l'evaluation du stade d'evolution de la maladie et l'etablissement du pronostic

Publications (1)

Publication Number Publication Date
CA2321259A1 true CA2321259A1 (fr) 1999-08-19

Family

ID=22121731

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002321259A Abandoned CA2321259A1 (fr) 1998-02-16 1999-02-16 Dosage de telomerase preleve dans des liquides organiques utilise pour le depistage du cancer, l'evaluation du stade d'evolution de la maladie et l'etablissement du pronostic

Country Status (5)

Country Link
EP (1) EP1071808A1 (fr)
JP (1) JP2002503480A (fr)
AU (1) AU2682299A (fr)
CA (1) CA2321259A1 (fr)
WO (1) WO1999041406A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106940372A (zh) * 2017-03-06 2017-07-11 南京中医药大学 检测端粒酶的亚甲基蓝、上转换纳米粒修饰纤维化纸传感器及其制备方法

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1158055A1 (fr) 2000-05-26 2001-11-28 Xu Qi University of Teaxs Laboratoire de Leucémie Chen Méthode pour le diagnostic de cancers
ITMI20022743A1 (it) 2002-12-23 2004-06-24 Ist Naz Stud Cura Dei Tumori Metodo per la determinazione del rischio di comparsa, della presenza o del decorso di malattie tumorali.
ATE406463T1 (de) 2005-04-06 2008-09-15 Maurice Stroun Methode zur krebsdiagnose mittels nachweis von dna und rna im kreislauf

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5830644A (en) * 1992-05-13 1998-11-03 Geron Corporation Method for screening for agents which increase telomerase activity in a cell
US5840490A (en) * 1995-06-07 1998-11-24 Mcmaster University Telomerase activity associated with hematological and colorectal malignancies

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106940372A (zh) * 2017-03-06 2017-07-11 南京中医药大学 检测端粒酶的亚甲基蓝、上转换纳米粒修饰纤维化纸传感器及其制备方法

Also Published As

Publication number Publication date
JP2002503480A (ja) 2002-02-05
EP1071808A1 (fr) 2001-01-31
WO1999041406A1 (fr) 1999-08-19
AU2682299A (en) 1999-08-30

Similar Documents

Publication Publication Date Title
US6607898B1 (en) Method for detection of hTR and hTERT telomerase-associated RNA in plasma or serum
Catarino et al. Quantification of free circulating tumor DNA as a diagnostic marker for breast cancer
JP4308309B2 (ja) グルタチオンＳトランスフェラーゼＰｉ発現に基づき化学療法を決定する方法
JP2000512126A (ja) 体液中の腫瘍細胞を数量化するための方法およびかかる方法に適合した試験キット
CN108949992B (zh) 一种与食管鳞癌及其分级相关的生物标志物
CN103710460A (zh) 定量检测egfr基因突变的试剂盒及其用途
CN101875972A (zh) Kras基因突变的快速检测
KR20030081339A (ko) Ｅｒｃｃ１ 및 ｔｓ 발현을 기초로 한 화학요법 섭생을결정하는 방법
US20220229060A1 (en) Gender-specific markers for diagnosing prognosis and determining treatment strategy for renal cancer patients
CN101875971A (zh) Braf基因突变的快速检测
Moul et al. Absent ras gene mutations in human adrenal cortical neoplasms and pheochromocytomas
CN101613748A (zh) 一种检测胰腺癌血清标志物的方法
EP3390661B1 (fr) Utilisation d'arn antisens longs non-codants pour le diagnostic du cancer de la prostate
US20190285518A1 (en) Methods for personalized detection of the recurrence of cancer or metastasis and/or evaluation of treatment response
CN106755343A (zh) 胰腺癌预后诊断分子标记物
RU2324186C1 (ru) Способ диагностики плоскоклеточного рака легких и набор для его осуществления
CA2321259A1 (fr) Dosage de telomerase preleve dans des liquides organiques utilise pour le depistage du cancer, l'evaluation du stade d'evolution de la maladie et l'etablissement du pronostic
KR102052398B1 (ko) 전립선암 진단용 바이오마커 및 이의 용도
US11542559B2 (en) Methylation-based biomarkers in breast cancer screening, diagnosis, or prognosis
RU2330285C1 (ru) Способ диагностики немелкоклеточного рака легких и набор для его осуществления
Perhavec et al. The hTERT mRNA in plasma samples of early breast cancer patients, non-cancer patients and healthy individuals
WO2023074135A1 (fr) Procédé et kit de réactifs pour aider à déterminer le pronostic du cancer pulmonaire
Zhang et al. Detection of the t (11; 18) API2/MALT1 translocation associated with gastric MALT lymphoma in routine formalin-fixed, paraffin-embedded small endoscopic biopsy specimens by robust real-time RT-PCR
Mankovskaya Preoperative Diagnostics of Papillary Thyroid Carcinoma by Molecular Analysis of FNAB Materials
CN118516459A (zh) 胰腺癌相关血清microRNA标志物及胰腺癌诊断方法

Legal Events

Date Code Title Description
FZDE Dead